|
21.12.2016 11:59:15
|
DGAP-Ad hoc: SYGNIS AG
DGAP-Adhoc: SYGNIS AG acquires profitable life sciences tools company C.B.S. Scientific for US $0.9 million in cash and shares
---------------------------------------------------------------------------
NOT FOR DISTRIBUTION, PUBLICATION, OR TRANSMISSION IN USA, CANADA, JAPAN AND AUSTRALIA
SYGNIS AG acquires profitable life sciences tools company C.B.S. Scientific for US $0.9 million in cash and shares
- C.B.S. estimated revenues in excess of $1,500,000 in 2016
- Profitable and cash generative
- Strong sales synergies and significant potential for future revenue growth
Madrid, Spain, and Heidelberg, Germany, 21 December, 2016 - SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the execution of a binding agreement for the acquisition of C.B.S. Scientific Company Inc. (C.B.S.), a profitable Life Sciences tools company located in San Diego, USA.
SYGNIS will pay a total consideration of $900,000 of which $540,000 is in cash, funded from existing cash balances and $360,000 in the form of 275,311 new shares in SYGNIS AG to be issued from authorized capital. Five- sixths (5/6) of the shares issued to C.B.S stock holders will be restricted from trading for six months from the date of the registration of the excecution of the respective capital increase. After this period of time, with the beginning of every month, one-sixth (1/6) of the new shares shall be released from the aforementioned lock-up rule.
The acquisition of C.B.S is anticipated to be earnings enhancing and cash generative from the onset. Current revenues are in excess of $1,500,000 p.a. and the strong synergies between the C.B.S and SYGNIS product portfolios, plus the sales and customer base provide a clear opportunity for solid post acquisition revenue growth. Combining the Expedeon business location in San Diego and C.B.S will allow additional cost savings.
**** End of ad hoc announcement ****
For further information, please contact:
SYGNIS AG Dr. Heikki Lanckriet Co-CEO/CSO Phone : +44 1223 873 364 Email: heikki.lanckriet@sygnis.com
Pilar de la Huerta Co-CEO/CFO Phone: +34 91 192 36 50 Email: pdelahuerta@sygnis.com
MC Services AG Raimund Gabriel Managing Partner Phone: +49 89 210228 0 Email: raimund.gabriel@mc-services.eu
About SYGNIS AG: www.sygnis.com
SYGNIS AG is specialized in the development and the commercialization of proprietary technologies and offers a wide range of different commercial products addressing key challenges in molecular biology. With the acquisition of Expedeon Holdings, Ltd. based in Cambridge, UK, SYGNIS has added a complementary proteomic product portfolio. Resulting from this significant expansion, SYGNIS' product portfolio now covers the entire workflow of molecular biology. The products are sold through a direct sales force and several distribution partners in Europe, the US and Asia. SYGNIS AG has offices in Germany, Spain and the UK, production sites in the UK and the US as well as sales offices in Asia. The company is listed on the German Stock Exchange in Frankfurt in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03).
### The information contained herein does not constitute an offer to sell or a solicitation of an offer to purchase any securities of SYGNIS AG in the Federal Republic of Germany nor under any other jurisdiction, in particular not where such kind of offer or solicitation is prohibited or lacks the required permission. Potential investors in securities of SYGNIS AG are asked to familiarize themselves with and to observe the respective restrictions.
The information in this document may not be disseminated outside the Federal Republic of Germany in particular not in the United States, to U.S. Persons (as defined in regulation S of the U.S. Securities Act of 1933) or to publications with a general circulation in the United States with the exception of a such disclosures or announcements outside the Federal Republic of Germany which have to be made under the respective mandatory law. Any person who fails to comply with these restrictions may violate the security laws of certain jurisdictions, in particular of the United States. Securities in SYGNIS AG are not publicly offered outside the Federal Republic of Germany.
Some statements included in this ad hoc announcement, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.###
---------------------------------------------------------------------------
21-Dec-2016 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English Company: SYGNIS AG Waldhofer Str. 104 69123 Heidelberg Germany Phone: +49 (0) 6221 3540 125 Fax: +49 (0) 6221 3540 127 E-mail: investors@sygnis.com Internet: www.sygnis.com ISIN: DE000A1RFM03 WKN: A1RFM0 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
End of Announcement DGAP News Service ---------------------------------------------------------------------------
532253 21-Dec-2016 CET/CEST
DGAP-Ad-hoc: SYGNIS AG / Key word(s): Takeover
SYGNIS AG acquires profitable life sciences tools company C.B.S. Scientific
for US $0.9 million in cash and shares
21-Dec-2016 / 11:59 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR, transmitted by
DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Ad hoc announcement according to § 17 MAR
---------------------------------------------------------------------------
NOT FOR DISTRIBUTION, PUBLICATION, OR TRANSMISSION IN USA, CANADA, JAPAN AND AUSTRALIA
SYGNIS AG acquires profitable life sciences tools company C.B.S. Scientific for US $0.9 million in cash and shares
- C.B.S. estimated revenues in excess of $1,500,000 in 2016
- Profitable and cash generative
- Strong sales synergies and significant potential for future revenue growth
Madrid, Spain, and Heidelberg, Germany, 21 December, 2016 - SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the execution of a binding agreement for the acquisition of C.B.S. Scientific Company Inc. (C.B.S.), a profitable Life Sciences tools company located in San Diego, USA.
SYGNIS will pay a total consideration of $900,000 of which $540,000 is in cash, funded from existing cash balances and $360,000 in the form of 275,311 new shares in SYGNIS AG to be issued from authorized capital. Five- sixths (5/6) of the shares issued to C.B.S stock holders will be restricted from trading for six months from the date of the registration of the excecution of the respective capital increase. After this period of time, with the beginning of every month, one-sixth (1/6) of the new shares shall be released from the aforementioned lock-up rule.
The acquisition of C.B.S is anticipated to be earnings enhancing and cash generative from the onset. Current revenues are in excess of $1,500,000 p.a. and the strong synergies between the C.B.S and SYGNIS product portfolios, plus the sales and customer base provide a clear opportunity for solid post acquisition revenue growth. Combining the Expedeon business location in San Diego and C.B.S will allow additional cost savings.
**** End of ad hoc announcement ****
For further information, please contact:
SYGNIS AG Dr. Heikki Lanckriet Co-CEO/CSO Phone : +44 1223 873 364 Email: heikki.lanckriet@sygnis.com
Pilar de la Huerta Co-CEO/CFO Phone: +34 91 192 36 50 Email: pdelahuerta@sygnis.com
MC Services AG Raimund Gabriel Managing Partner Phone: +49 89 210228 0 Email: raimund.gabriel@mc-services.eu
About SYGNIS AG: www.sygnis.com
SYGNIS AG is specialized in the development and the commercialization of proprietary technologies and offers a wide range of different commercial products addressing key challenges in molecular biology. With the acquisition of Expedeon Holdings, Ltd. based in Cambridge, UK, SYGNIS has added a complementary proteomic product portfolio. Resulting from this significant expansion, SYGNIS' product portfolio now covers the entire workflow of molecular biology. The products are sold through a direct sales force and several distribution partners in Europe, the US and Asia. SYGNIS AG has offices in Germany, Spain and the UK, production sites in the UK and the US as well as sales offices in Asia. The company is listed on the German Stock Exchange in Frankfurt in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03).
### The information contained herein does not constitute an offer to sell or a solicitation of an offer to purchase any securities of SYGNIS AG in the Federal Republic of Germany nor under any other jurisdiction, in particular not where such kind of offer or solicitation is prohibited or lacks the required permission. Potential investors in securities of SYGNIS AG are asked to familiarize themselves with and to observe the respective restrictions.
The information in this document may not be disseminated outside the Federal Republic of Germany in particular not in the United States, to U.S. Persons (as defined in regulation S of the U.S. Securities Act of 1933) or to publications with a general circulation in the United States with the exception of a such disclosures or announcements outside the Federal Republic of Germany which have to be made under the respective mandatory law. Any person who fails to comply with these restrictions may violate the security laws of certain jurisdictions, in particular of the United States. Securities in SYGNIS AG are not publicly offered outside the Federal Republic of Germany.
Some statements included in this ad hoc announcement, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.###
---------------------------------------------------------------------------
21-Dec-2016 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English Company: SYGNIS AG Waldhofer Str. 104 69123 Heidelberg Germany Phone: +49 (0) 6221 3540 125 Fax: +49 (0) 6221 3540 127 E-mail: investors@sygnis.com Internet: www.sygnis.com ISIN: DE000A1RFM03 WKN: A1RFM0 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
End of Announcement DGAP News Service ---------------------------------------------------------------------------
532253 21-Dec-2016 CET/CEST
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Expedeon (ex Sygnis)mehr Nachrichten
| Keine Nachrichten verfügbar. |
Analysen zu Expedeon (ex Sygnis)mehr Analysen
Letzte Top-Ranking Nachrichten
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.